miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines

Biochemical and Biophysical Research Communications

Volumn 403, Issue 1, 2010, Pages 120-125

  Henry, Jon C ^a   Park, Jong Kook ^b   Jiang, Jinmai ^b   Kim, Ji Hye ^b   Nagorney, David M ^c   Roberts, Lewis R ^c   Banerjee, Soma ^d   Schmittgen, Thomas D ^b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c MAYO CLINIC   (United States)

^d INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Cancer; HCC; Liver; MicroRNA mimetic; MiR 199a*

Indexed keywords

DOXORUBICIN; HERMES ANTIGEN; HYALURONIC ACID; MICRORNA 199A 3P; OLIGONUCLEOTIDE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL INVASION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, CD44; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENES, TUMOR SUPPRESSOR; HUMANS; LIVER NEOPLASMS; MICRORNAS; NEOPLASM INVASIVENESS;

EID: 78649697501     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.10.130     Document Type: Article

References (27)

1. Gramantieri L., Fornari F., Callegari E., Sabbioni S., Lanza G., Croce C.M., Bolondi L., Negrini M. MicroRNA involvement in hepatocellular carcinoma. J. Cell. Mol. Med. 2008, 12:2189-2204.
2. P. Pineau, S. Volinia, K. McJunkin, A. Marchio, C. Battiston, B. Terris, V. Mazzaferro, S.W. Lowe, C.M. Croce, A. Dejean, miR-221 overexpression contributes to liver tumorigenesis. Proc. Natl. Acad. Sci. USA (2009).
3. Meng F., Henson R., Wehbe-Janek H., Ghoshal K., Jacob S.T., Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133:647-658.
4. Kutay H., Bai S., Datta J., Motiwala T., Pogribny I., Frankel W., Jacob S.T., Ghoshal K. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J. Cell. Biochem. 2006, 99:671-678.
5. Murakami Y., Yasuda T., Saigo K., Urashima T., Toyoda H., Okanoue T., Shimotohno K. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006, 25:2537-2545.
6. E. Elyakim, E. Sitbon, A. Faerman, S. Tabak, E. Montia, L. Belanis, A. Dov, E.G. Marcusson, C.F. Bennett, A. Chajut, D. Cohen, N. Yerushalmi, hsa-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy, Cancer Res. (2010).
7. Fornari F., Milazzo M., Chieco P., Negrini M., Calin G.A., Grazi G.L., Pollutri D., Croce C.M., Bolondi L., Gramantieri L. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 2010, 70:5184-5193.
8. Gramantieri L., Ferracin M., Fornari F., Veronese A., Sabbioni S., Liu C.G., Calin G.A., Giovannini C., Ferrazzi E., Grazi G.L., Croce C.M., Bolondi L., Negrini M. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res. 2007, 67:6092-6099.
9. Jiang J., Gusev Y., Aderca I., Mettler T.A., Nagorney D.M., Brackett D.J., Roberts L.R., Schmittgen T.D. Association of microRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin. Cancer Res. 2008, 14:419-427.
10. Kim S., Lee U.J., Kim M.N., Lee E.J., Kim J.Y., Lee M.Y., Choung S., Kim Y.J., Choi Y.C. MicroRNA miR-199a* regulates the MET proto-oncogene and the downstream extracellular signal-regulated kinase 2 (ERK2). J. Biol. Chem. 2008, 283:18158-18166.
11. Kaposi-Novak P., Lee J.S., Gomez-Quiroz L., Coulouarn C., Factor V.M., Thorgeirsson S.S. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J. Clin. Invest. 2006, 116:1582-1595.
12. Murakami Y., Aly H.H., Tajima A., Inoue I., Shimotohno K. Regulation of the hepatitis C virus genome replication by miR-199a. J. Hepatol. 2009, 50:453-460.
13. Dolganiuc A., Petrasek J., Kodys K., Catalano D., Mandrekar P., Velayudham A., Szabo G. MicroRNA expression profile in Lieber-DeCarli diet-induced alcoholic and methionine choline deficient diet-induced nonalcoholic steatohepatitis models in mice. Alcohol. Clin. Exp. Res. 2009, 33:1704-1710.
14. Zhang G.L., Li Y.X., Zheng S.Q., Liu M., Li X., Tang H. Suppression of hepatitis B virus replication by microRNA-199a-3p and microRNA-210. Antiviral Res. 2010, 88:169-175.
15. Taulli R., Bersani F., Foglizzo V., Linari A., Vigna E., Ladanyi M., Tuschl T., Ponzetto C. The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation. J. Clin. Invest. 2009, 119:2366-2378.
16. Liang Y., Ridzon D., Wong L., Chen C. Characterization of microRNA expression profiles in normal human tissues. BMC Genomics 2007, 8:166.
17. Orian-Rousseau V., Chen L., Sleeman J.P., Herrlich P., Ponta H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev. 2002, 16:3074-3086.
18. Migliore C., Petrelli A., Ghiso E., Corso S., Capparuccia L., Eramo A., Comoglio P.M., Giordano S. MicroRNAs impair MET-mediated invasive growth. Cancer Res. 2008, 68:10128-10136.
19. Lara-Pezzi E., Serrador J.M., Montoya M.C., Zamora D., Yanez-Mo M., Carretero M., Furthmayr H., Sanchez-Madrid F., Lopez-Cabrera M. The hepatitis B virus X protein (HBx) induces a migratory phenotype in a CD44-dependent manner: possible role of HBx in invasion and metastasis. Hepatology 2001, 33:1270-1281.
20. Rudzki Z., Jothy S. CD44 and the adhesion of neoplastic cells. Mol. Pathol. 1997, 50:57-71.
21. Screaton G.R., Bell M.V., Jackson D.G., Cornelis F.B., Gerth U., Bell J.I. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc. Natl. Acad. Sci. USA 1992, 89:12160-12164.
22. Tolg C., Hofmann M., Herrlich P., Ponta H. Splicing choice from ten variant exons establishes CD44 variability. Nucleic Acids Res. 1993, 21:1225-1229.
23. Endo K., Terada T. Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival. J. Hepatol. 2000, 32:78-84.
24. Yang G.H., Fan J., Xu Y., Qiu S.J., Yang X.R., Shi G.M., Wu B., Dai Z., Liu Y.K., Tang Z.Y., Zhou J. Osteopontin combined with CD44, a novel prognostic biomarker for patients with hepatocellular carcinoma undergoing curative resection. Oncologist 2008, 13:1155-1165.
25. Xie Z., Choong P.F., Poon L.F., Zhou J., Khng J., Jasinghe V.J., Palaniyandi S., Chen C.S. Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasion. Cancer Chemother. Pharmacol. 2008, 62:949-957.
26. Zhu Z., Hao X., Yan M., Yao M., Ge C., Gu J., Li J. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int. J. Cancer 2010, 126:2067-2078.
27. Shao W., Chen J.B., Wang F., Xia J.J., Qi Z.Q. Combined application of blocking antibodies and microRNA interference in inhibiting CD44 expression. Transplant. Proc. 2010, 42:2777-2781.